Targeting solid tumors with non-pathogenic obligate anaerobic bacteria

Area of Science:

• Oncology
• Microbiology
• Drug Discovery

Background:

• Molecular-targeting cancer drugs face resistance due to tumor cell instability and cancer stem cells.
• Tumor microenvironments, characterized by hypoxia (low oxygen) and low pH, contribute to treatment resistance.
• Hypoxia has traditionally been viewed as a barrier, but it presents an opportunity for targeted therapies.

Purpose of the Study:

• To highlight the potential of exploiting anaerobic conditions within solid tumors as a therapeutic target.
• To introduce the use of bacteria as targeted delivery vehicles for cancer treatment.
• To review the development and rationale of using Bifidobacterium longum for solid tumor therapy.

Main Methods:

• Reviewing existing literature on bacterial utility in cancer therapy.
• Presenting ongoing research and trials utilizing anaerobic bacteria.
• Focusing on the development of Bifidobacterium longum as a non-pathogenic anaerobic bacterium for targeting solid cancers.

Main Results:

• Demonstrated the feasibility of using anaerobic conditions in tumors as a selective targeting mechanism.
• Highlighted Bifidobacterium longum's ability to selectively recognize and target hypoxic solid tumor tissues.
• Discussed the paradox of enhanced angiogenesis coexisting with low oxygen pressure in tumor masses.

Conclusions:

• Anaerobic bacteria offer a promising strategy to overcome drug resistance in cancer treatment.
• Bifidobacterium longum serves as a viable bacterial vehicle for selectively targeting solid tumors.
• This novel approach holds significant potential for future cancer therapy development.